Skip to main content

Drug Interactions between capmatinib and Naropin SDV

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ROPivacaine capmatinib

Applies to: Naropin SDV (ropivacaine) and capmatinib

GENERALLY AVOID: Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of CYP450 1A2 isoenzyme. Coadministration with capmatinib increased the systemic exposure (AUC0-INF) of caffeine (a CYP450 1A2 substrate) by 134%, but did not affect the peak plasma concentration (Cmax) of caffeine.

MANAGEMENT: Coadministration of capmatinib with drugs that are substrates of CYP450 1A2 should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and the dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.

References

  1. (2020) "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer